Shareholders in home health company Amedisys have approved its $3.3 billion union with Optum, even as the feds take a closer look at the deal.
Amedisys issued a filing with the Securities and Exchange Commission on Friday to confirm the shareholders' vote. The shareholders also signed off on compensation that could be paid to the executive team as part of the merger, according to the filing.
It was revealed in late June that healthcare giant UnitedHealth Group had won a bidding war to scoop up Amedisys, further bolstering the home health capabilities of its Optum subsidiary. The all-cash deal beat out an all-stock offer from Option Care Health.
Amedisys agreed to the deal with Option Care in May, and the infusion therapy provider will receive a $106 million termination fee.
In mid-August, Amedisys disclosed in a filing that the Department of Justice had issued a second request for information on the deal, extending its probe.
UnitedHealth has been in the market for home health assets and earlier this year closed a $5.4 billion buy of LHC Group.